Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiarrhythmic Drug Development: Classification and its Impact on Development.

E.M. Vaughan Williams

    American Journal of Therapeutics
    |April 1, 1995
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Abrocitinib as a Novel Therapeutic Option for Elastolytic Giant Cell Granuloma: A Case Report.

    American journal of therapeutics·2026
    Same journal

    Dupilumab for Lichen Amyloidosis in an Elderly Multimorbid Patient.

    American journal of therapeutics·2026
    Same journal

    Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

    American journal of therapeutics·2026
    Same journal

    Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

    American journal of therapeutics·2026
    Same journal

    Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

    American journal of therapeutics·2026
    Same journal

    Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

    American journal of therapeutics·2026

    Identifying patients at risk of sudden cardiac death is crucial for effective antiarrhythmic therapy. New Class 3 agents, like low-dose amiodarone, show promise in reducing mortality and arrhythmias without complete suppression.

    Area of Science:

    • Cardiology
    • Electrophysiology
    • Pharmacology

    Background:

    • Current methods for classifying arrhythmia severity, such as the Lown classification, are inadequate.
    • Identifying patients at high risk of sudden cardiac death is essential for guiding antiarrhythmic therapy.
    • Recent research focuses on electrophysiological markers like dispersion of depolarization and repolarization.

    Purpose of the Study:

    • To explore improved methods for identifying patients at risk of sudden cardiac death.
    • To evaluate the efficacy of novel antiarrhythmic agents, particularly Class 3 drugs.
    • To assess the impact of low-dose amiodarone on mortality and serious arrhythmias.

    Main Methods:

    • Utilizing signal averaging of the terminal QRS complex to measure depolarization dispersion.

    Related Experiment Videos

  • Comparing QT intervals across different ECG leads to assess repolarization dispersion.
  • Analyzing outcomes from clinical trials investigating new antiarrhythmic therapies, including amiodarone.

    • Main Results:

    • The Lown classification for arrhythmia severity has proven unsatisfactory.
    • Dispersion of depolarization and repolarization are emerging markers for risk stratification.
    • Low-dose amiodarone has demonstrated significant reductions in mortality and serious arrhythmias, even without complete arrhythmia abolition.

    Conclusions:

    • Improved risk stratification for sudden cardiac death is needed in antiarrhythmic therapy.
    • Class 3 antiarrhythmic agents, including amiodarone, represent a promising therapeutic avenue.
    • Low-dose amiodarone offers a viable strategy for managing arrhythmias and reducing mortality.